Imiquimod 5 % Topical Cream
RxNorm 310982
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 310982 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: imiquimod 5 % Topical Cream.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Imiquimod 50 mg/ML Topical Cream
(Atom ID: 1431346)
PSNPrescribable
Prescribable Name (PSN):
Imiquimod 5 % Topical Cream
(Atom ID: 6373383)
SYPrescribable
Synonym (SY):
Imiquimod 5 % Topical Cream
(Atom ID: 3061004)
PTPrescribable
Designated preferred name (PT):
Imiquimod 50 mg/g cutaneous cream
(Atom ID: 12871792)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely imiquimod 50 mg/1 gram conventional release cutaneous cream (clinical drug)
(Atom ID: 12872132)
Patient Education
Imiquimod Topical
Imiquimod cream is used to treat certain types of actinic keratoses (flat, scaly growths on the skin caused by too much sun exposure) on the face or scalp. Imiquimod cream is also used to treat superficial basal cell carcinoma (a type of skin cancer) on the trunk, neck, arms, hands, legs, or feet and warts on the skin of the genital and anal areas. Imiquimod is in a class of medications called immune response modifiers. It treats genital and anal warts by increasing the activity of the body's immune system. It is not known exactly how imiquimod cream works to treat actinic keratoses or superficial basal cell carcinoma. Imiquimod cream does not cure warts, and new warts may appear during treatment. It is not known whether imiquimod cream prevents the spread of warts to other people.
[Learn More]
* Please review the disclaimer below.